Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Conventional and Pretargeted Radioimmunotherapy Using Bismuth-213 to Target and Treat Non-Hodgkin Lymphomas Expressing CD20: A Preclinical Model toward Optimal Consolidation Therapy to Eradicate Minimal Residual Disease.
Blood (2010)
  • Steven I. Park, University of North Carolina at Chapel Hill
  • Jaideep Shenoi, Fred Hutchinson Cancer Research Center
  • John M. Pagel, Tokyo Medical and Dental University
  • Donald K. Hamlin, University of Washington
  • D. Scott Wilbur, University of Washington
  • Nural Orgun, Fred Hutchinson Cancer Research Center
  • Aimee L. Kenoyer, Fred Hutchinson Cancer Research Center
  • Shani Frayo, Fred Hutchinson Cancer Research Center
  • Amanda Axtman, Fred Hutchinson Cancer Research Center
  • Tom Back, University of Gothenburg
  • Yukang Lin, Fred Hutchinson Cancer Research Center
  • Darrell R. Fisher, Pacific Northwest National Laboratory
  • Ajay K. Gopal, Fred Hutchinson Cancer Research Center
  • Damian J. Green, Fred Hutchinson Cancer Research Center
  • Oliver W. Press, Fred Hutchinson Cancer Research Center
Link
Disciplines
Publication Date
November 18, 2010
DOI
10.1182/blood-2010-05-282327
Citation Information
Steven I. Park, Jaideep Shenoi, John M. Pagel, Donald K. Hamlin, et al.. "Conventional and Pretargeted Radioimmunotherapy Using Bismuth-213 to Target and Treat Non-Hodgkin Lymphomas Expressing CD20: A Preclinical Model toward Optimal Consolidation Therapy to Eradicate Minimal Residual Disease." Blood Vol. 116 Iss. 20 (2010) p. 4231 - 4239
Available at: http://works.bepress.com/john-pagel/217/